Happy New Year to all my readers! Some companies that are R&D powerhouses spend years doing pioneering research in biotechnology. While that is good for the progress of medicine, financially, your medicine is only as good as its patent coverage. Arrowhead (ARWR) is such an R&D behemoth in the RNAi...
Avisol Capital Partners on Seeking Alpha | December 30, 2020
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Cardiometabolic Programs Offer Enormous Potential In November 2020, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) hosted KOL events for its lead cardiometabolic programs, ARO-APOC3 and ARO-ANG3. The company had previously announced encouraging results for each of those programs (see our previous update here ) and